Skip to main content

Aurora Cannabis Inc. (21P1.F)

FSX Healthcare Drug Manufacturers - Specialty & GenericView data quality →
43.3Fair

ValueMarkers Composite Index

Top 12%#39,424 of 44,707

DCF data not available

Piotroski
5/9
Neutral
Beneish
-1.78
Investigate
Altman
-10.01
Distress
DCF Value
-
N/A
ROIC
-0.6%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Aurora Cannabis Inc. (21P1.F) — VMCI valuation read

Aurora Cannabis Inc. (21P1.F) carries a VMCI composite of 43/100, 7 points below the Healthcare sector median of 50. Among mid-cap names, that gap places 21P1.F in the bottom third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The 21P1.F insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads 21P1.F trades at 18.0x earnings, 0% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 0.4x leaves covenant headroom, the line to track on Aurora Cannabis Inc.'s next 10-Q.

21P1.F rose 3.9% over the trailing 7 days, with a -16.3% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 21P1.F’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.